Coronary Thermodilution Waveforms After Acute Reperfused ST-Segment–Elevation Myocardial Infarction: Relation to Microvascular Obstruction and Prognosis

Shu Ning Yew, BMedSci, MBChB;* David Carrick, MRCGP, PhD, FRCP;* David Corcoran, BMEdSci, MRCP; Nadeem Ahmed, BMEdSci, MRCP, MBChB; Jaclyn Carberry, BMEdSci, MBChB(Hons); Vannesa Teng Yue May, BMEdSci, MBChB; Margaret McEntegart, PhD, FRCP; Mark C. Petrie, MRCGP; Hany Eteiba, MD, FRCP; Mitchell Lindsay, MD, FRCP; Stuart Hood, MD, FRCP; Stuart Watkins, MD, FRCP; Andrew Davie, MD, FRCP; Ahmed Mahrour, MD; Ify Mordi, MD, MRCP; Ian Ford, PhD; Keith G. Oldroyd, MD(Hons), FRCP; Colin Berry, PhD, FRCP

Background—Invasive measures of microvascular resistance in the culprit coronary artery have potential for risk stratification in acute ST-segment–elevation myocardial infarction. We aimed to investigate the pathological and prognostic significance of coronary thermodilution waveforms using a diagnostic guidewire.

Methods and Results—Coronary thermodilution was measured at the end of percutaneous coronary intervention (PCI) and contrast-enhanced cardiac magnetic resonance imaging (MRI) was intended on day 2 and 6 months later to assess left ventricular (LV) function and pathology. All-cause death or first heart failure hospitalization was a pre-specified outcome (median follow-up duration 1469 days). Thermodilution recordings underwent core laboratory assessment. A total of 278 patients with acute ST-segment elevation myocardial infarction EMI (72% male, 59±11 years) had coronary thermodilution measurements classified as narrow unimodal (n=143 [51%]), wide unimodal (n=100 [36%]), or bimodal (n=35 [13%]). Microvascular obstruction and myocardial hemorrhage were associated with the thermodilution waveform pattern (P=0.007 and 0.011, respectively), and both pathologies were more prevalent in patients with a bimodal morphology. On multivariate analysis with baseline characteristics, thermodilution waveform status was a multivariable associate of microvascular obstruction (odds ratio [95% confidence interval]=5.29 [1.73, 16.22]; P=0.004) and myocardial hemorrhage (3.45 [1.16, 10.26]; P=0.026), but the relationship was not significant when index of microvascular resistance (IMR) >40 or change in index of microvascular resistance (5 per unit) was included. However, a bimodal thermodilution waveform was independently associated with all-cause death and hospitalization for heart failure (odds ratio [95% confidence interval]=2.70 [1.10, 6.63]; P=0.031), independent of index of microvascular resistance≥40, ST-segment resolution, and TIMI (Thrombolysis in Myocardial Infarction) Myocardial Perfusion Grade.

Conclusions—The thermodilution waveform in the culprit coronary artery is a biomarker of prognosis and may be useful for risk stratification immediately after reperfusion therapy. (J Am Heart Assoc. 2018;7:e008957. DOI: 10.1161/JAHA.118.008957.)

Key Words: magnetic resonance imaging • myocardial infarction • pathophysiology

Percutaneous coronary intervention (PCI) for acute ST-elevation myocardial infarction (STEMI) routinely leads to successful coronary reperfusion.1,2 However, failed myocardial reperfusion, depicted by microvascular obstruction on contrast-enhanced cardiac magnetic resonance (CMR) imaging, occurs in more than half of these patients,3,4 implicating an adverse long-term prognosis.5,6 Microvascular obstruction usually passes undetected in clinical practice. Standard measures of myocardial reperfusion, including TIMI (Thrombolysis in Myocardial Infarction)
Thermodilution Waveforms in Acute STEMI  
Yew et al  
DOI: 10.1161/JAHA.118.008957  
Journal of the American Heart Association

**Clinical Perspective**

**What Is New?**
- In acute ST-segment-elevation myocardial infarction survivors, coronary thermodilution waveforms depicted using a diagnostic guidewire at the end of percutaneous coronary intervention provides information that is linked with microvascular injury.
- A bimodal thermodilution waveform is independently associated with adverse clinical outcomes, including all-cause death and heart failure in the longer term.
- A bimodal thermodilution waveform is a biomarker for prognostication in survivors of acute ST-segment-elevation myocardial infarction.

**What Are the Clinical Implications?**
- Risk assessment of failed reperfusion in patients undergoing emergency percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction is challenging.
- Use of a diagnostic guidewire at the end of the percutaneous coronary intervention has emerging clinical utility for risk assessment.
- Classification of the coronary thermodilution waveform categorization is a novel approach to identify at-risk subgroups that has the potential to translate into real-world practice merits assessment.

Myocardial Perfusion Grade and corrected frame count, or ST-segment resolution on the ECG, lack sensitivity and reproducibility.

CMR is the reference noninvasive technique for detection of microvascular pathology, however, CMR is neither feasible acutely nor widely available and is not routinely recommended in contemporary practice guidelines.

The index of microvascular resistance (IMR) is a direct invasive measure of microvascular function that can be performed routinely in the cardiac catheterization laboratory immediately after revascularization to identify patients with failed reperfusion. IMR is inversely associated with left ventricular (LV) function post-MI and positively associated with infarct size and pathology. An IMR >40 is a multivariable associate of mortality post-STEMI.

Because downstream microvascular resistance influences coronary blood flow, the characteristics of the thermodilution waveform in the culprit coronary artery reflect microvascular dysfunction and infarct pathology in patients with acute STEMI. In a study of 88 patients with acute STEMI, a bimodal thermodilution waveform in the culprit coronary artery was associated with microvascular dysfunction and cardiac death at 6 months after STEMI, in contrast to IMR. However, this analysis had some limitations including a modest sample size, short duration of follow-up (6 months), and lack of follow-up imaging. We aimed to further assess the clinical significance of the thermodilution waveform in the culprit coronary artery in a large and relatively unselected population of STEMI survivors.

**Methods**

The data, analytic methods, and study materials will be made available on request to other researchers for purposes of reproducing the results or replicating the procedure. The study was approved by the West of Scotland Research Ethics Committee, reference 10-S0703-28, and informed consent was obtained from each patient.

**Study Population**

Between July 14, 2011 and November 22, 2012, 278 STEMI patients with acute STEMI who were reperfused predominantly by emergency PCI were prospectively enrolled (British Heart Foundation MR-MI; ClinicalTrials.gov: NCT02072850). All patients gave informed consent to undergo a diagnostic guidewire-based assessment at the end of the PCI procedure, then CMR 2 days and 6 months later, and follow-up for health outcomes in the longer term. Patients with a contraindication to CMR, such as a pacemaker or severe renal dysfunction, were not enrolled.

**Thermodilution in the Culprit Coronary Artery**

Thermodilution curves were manually acquired after PCI of the infarct-related artery using a dual-sensor pressure- and temperature-sensitive coronary guidewire (Abbott Vascular, Santa Clara, CA). The diagnostic wire was calibrated outside the body, equalized with aortic pressure at the ostium of the guide catheter, and then advanced to the distal third of the culprit artery. We used guide catheters without side holes to allow delivery of a saline bolus into the coronary ostium. Care was also taken to ensure that the guide catheter was properly intubated and that the catheter was flushed with saline, thereby removing contrast medium that could potentially interfere with the measurements. The injections were preceded by a 2-mL bolus of 200 µg of nitrate.

Thermodilution curves in the culprit coronary artery were obtained by repeated manual injections of 3 mL of room-temperature saline during maximal hyperemia induced by continuous intravenous infusion of adenosine (140 µg/kg-min). The average of the 3 values was taken as the mean hyperemic transit time. Following injection of the saline bolus into the coronary artery, the reduction in temperature of the coronary blood was detected by the thermistor at the distal end of the guidewire. The thermodilution curve (time [seconds] on x-axis, temperature on y-axis) was recorded in real time (RADIAnalyzer, Abbott Vascular, Santa Clara, CA) and available for analysis (Radview 2.2, St Jude Medical, St. Paul, MN). IMR was calculated as the product of simultaneously measured...
distal coronary pressure (mm Hg) and mean hyperemic transit time (seconds), as previously described.\textsuperscript{12,13}

Assessment of Coronary Thermodilution Waveforms
Thermodilution waveforms were analyzed by a trained observer (S.N.Y.) who was blind to all of the magnetic resonance imaging (MRI) and clinical data. S.N.Y was trained and supported by D.C. and C.B. The waveforms were classified into 3 groups according to the shape of the thermodilution curve: sharp unimodal, wide unimodal, and bimodal (Figure 1). The mean transit time from the start of the thermodilution curve (reduction in temperature) to the maximum reduction in temperature of all the unimodal thermodilution curves was measured (mean [SD]=0.42 [0.15] seconds). A narrow unimodal waveform was defined as an acute temperature reduction followed by rapid return to the resting temperature, with a time from the beginning of the reduction to the minimum temperature (trough) of less than 0.42 seconds. A wide unimodal waveform was defined as a temperature decrease to a nadir followed by gradual return to the baseline temperature with a time from the inflection of the curve to the minimum temperature of more than 0.42 seconds. A bimodal waveform was defined as a waveform with 2 distinct nadirs (defined as the second nadir being lower than 20% of the peak temperature drop). Intra- and interobserver (S.N.Y. and D.C.) variabilities were assessed. Following completion of these analyses, the database was then closed before association with the MRI and clinical data.

Cardiac MRI Protocol
CMR was performed on a Siemens MAGNETOM Avanto (Erlangen, Germany) 1.5-Tesla scanner with a 12-element phased-array cardiac surface coil\textsuperscript{15} on day 2 and 6 months after reperfusion. CMR provided the reference data on LV function, pathology, and surrogate outcomes independent of the invasive tests. The images were analyzed by observers with at least 3 years of CMR experience (N.A., D.C., I.M.) and were reviewed by an experienced cardiologist (C.B.). The CMR images were assessed independently of the coronary thermodilution data.

Infarct Size, Microvascular Obstruction, and Myocardial Hemorrhage
The presence of acute infarction was established based on abnormalities in cine wall motion, rest first-pass myocardial perfusion, and delayed-enhancement imaging in 2 imaging planes.\textsuperscript{16} Microvascular obstruction was defined as a dark zone on early gadolinium enhancement imaging 1, 3, and 5 minutes postcontrast injection that remained present within an area of late gadolinium enhancement at 15 minutes. On the T2* CMR maps, a region of reduced signal intensity within the infarcted area, with a T2* value of <20 milliseconds\textsuperscript{17-20} was considered to confirm the presence of myocardial hemorrhage.

Myocardial Edema and Salvage
The extent of myocardial edema was defined as LV myocardium with pixel values (T2) >2 standard deviations from remote myocardium.\textsuperscript{21-26} Myocardial salvage was calculated by subtraction of percentage infarct size from percentage area at risk, as reflected by the extent of edema.\textsuperscript{23,26,27} The myocardial salvage index was calculated by dividing the myocardial salvage area by the initial area at risk.

ECG Analysis
A 12-lead ECG was obtained before coronary reperfusion and 60 minutes afterwards. The extent of ST-segment resolution on the ECG assessed 60 minutes after reperfusion compared to the baseline ECG before reperfusion\textsuperscript{28} was expressed as complete (≥70%), incomplete (30% to <70%), or none (≤30%).

Coronary Angiogram Acquisition and Analyses
Coronary angiograms were acquired during usual care with cardiac catheter laboratory x-ray (Innova\textsuperscript{®}; GE Healthcare, Chicago, IL) and information technology equipment (Centricity\textsuperscript{®}; GE Healthcare). The angiograms were analyzed by trained observers (J.C., V.T.Y.M.) who were blinded to all other clinical and MRI data. The TIMI coronary flow grade\textsuperscript{29} and frame count\textsuperscript{30} were assessed at initial angiography and at the end of the procedure. TIMI myocardial perfusion grade\textsuperscript{31} was assessed at the end of the procedure (Data S1).

Laboratory Analyses
The acquisition of blood samples for biochemical and hematologic analyses is described in Data S1.

Predefined Health Outcomes
We predefined adverse health outcomes that are pathophysio-logically linked with the natural history of myocardial infarction and LV remodeling.\textsuperscript{31,32} The primary composite outcome was all-cause death or a first heart failure event following the initial hospitalization (Data S1). These outcomes were independently assessed by a cardiologist who was blinded to the baseline data.

Statistical Analyses
Continuous variables were presented as means with standard deviation if they were normally distributed. If not, they were presented as medians with interquartile range. Differences in continuous variables between groups were assessed by the Student t test or ANOVA if the data were normally distributed or by the nonparametric Mann-Whitney test or Kruskal-Wallis.
test if the data were not normally distributed. Categorical variables are expressed as the number and percentage of patients. Differences in categorical variables between groups were assessed using a Fisher test.

Twenty subjects were randomly selected from the 278 patients, and the thermodilution pattern of these 20 subjects was analyzed repeatedly. The interobserver (D.C. and S.N.Y.) and intraobserver reliability for the visual assessment of thermodilution waveforms was assessed using weighted Cohen $\kappa$. Univariable and multivariable associations were assessed using binary logistic regression or linear regression. Logistic regression was used to identify potential clinical predictors of all-cause death or heart failure hospitalization, including patient characteristics, CMR findings, IMR, and thermodilution waveform pattern. The Akaike information criterion was used to assess the relative quality of the statistical models. All P-values are 2-sided, and a $P$-value of more than 0.05 indicates the absence of statistically significant effect. Statistical analyses were performed using SPSS version 22 (IBM, Armonk, NY).

**Results**

**Patient Characteristics**

A total of 278 patients had thermodilution performed in the culprit coronary artery (Table 1; Figure 2). Of these, 143 (51%) had a narrow unimodal waveform, 100 (36%) patients had a wide unimodal waveform, and 35 (13%) patients had a bimodal waveform. Representative cases are illustrated in Figure 1. The intraobserver variability and interobserver variability were $\kappa=0.740$ and 0.706, respectively.

The patients with a bimodal coronary thermodilution morphology had more adverse clinical characteristics, including an occluded culprit coronary artery at presentation ($P=0.007$),
Table 1. Characteristics of the Patients Grouped by the Type of Thermodilution Waveform in the Culprit Coronary Artery at the End of PCI

| Characteristics                        | All Patients n=278 | Narrow Unimodal n=143 (51%) | Wide Unimodal n=100 (36%) | Bimodal n=35 (13%) | P Value |
|----------------------------------------|--------------------|-----------------------------|---------------------------|--------------------|---------|
| Age, y                                 | 59±11              | 58±11                       | 61±11                     | 62±12              | 0.114   |
| Male, n (%)                            | 199 (72)           | 99 (69)                     | 76 (76)                   | 24 (69)            | 0.474   |
| BMI, kg/m²                             | 29±5               | 29±5                        | 29±4                      | 28±5               | 0.632   |
| Hypertension, n (%)                    | 87 (31)            | 45 (32)                     | 28 (28)                   | 14 (40)            | 0.399   |
| Current smoking, n (%)                 | 175 (63)           | 95 (66)                     | 59 (59)                   | 21 (60)            | 0.451   |
| Diabetes mellitus, n (%)*              | 32 (12)            | 17 (12)                     | 12 (12)                   | 3 (9)              | 0.930   |
| Previous myocardial infarction, n (%) | 18 (7)             | 13 (9)                      | 3 (3)                     | 2 (6)              | 0.154   |
| Previous PCI, n (%)                    | 14 (5)             | 8 (6)                       | 4 (4)                     | 2 (6)              | 0.797   |
| Presenting characteristics             |                    |                             |                           |                    |         |
| Heart rate, bpm                        | 78±17              | 78±17                       | 77±17                     | 80±15              | 0.575   |
| Systolic blood pressure, mm Hg         | 135±25             | 135±26                      | 136±25                    | 132±23             | 0.752   |
| Symptom onset to reperfusion, min      | 256±211            | 259±229                     | 244±186                   | 277±208            | 0.731   |
| Killip class, n (%)                    |                    |                             |                           |                    |         |
| I                                      | 198 (71)           | 110 (77)                    | 72 (72)                   | 16 (46)            | 0.003   |
| II                                     | 59 (21)            | 26 (18)                     | 22 (22)                   | 11 (4)             |         |
| III/IV                                 | 21 (8)             | 7 (5)                       | 6 (6)                     | 8 (23)             |         |
| ST-segment resolution post-PCI, n (%)  |                    |                             |                           |                    |         |
| Complete, ≥70%                         | 126 (46)           | 67 (47)                     | 48 (48)                   | 11 (31)            | 0.473   |
| Incomplete, 30% to <70%                | 113 (41)           | 57 (40)                     | 18 (51)                   | 38 (38)            |         |
| None, <30%                             | 38 (14)            | 18 (13)                     | 14 (14)                   | 6 (17)             |         |
| IMR>40                                 | 84 (30)            | 16 (11)                     | 45 (45)                   | 23 (66)            | <0.001  |
| Reperfusion strategy, n (%)†           |                    |                             |                           |                    |         |
| Primary PCI                            | 257 (92)           | 135 (94)                    | 88 (88)                   | 34 (97)            | 0.369   |
| Number of diseased arteries, n (%)     |                    |                             |                           |                    |         |
| 1                                      | 153 (55)           | 83 (58)                     | 50 (50)                   | 20 (57)            | 0.475   |
| 2                                      | 85 (31)            | 45 (32)                     | 30 (30)                   | 10 (29)            |         |
| 3                                      | 36 (13)            | 14 (10)                     | 17 (17)                   | 5 (14)             |         |
| Left main                              | 4 (1)              | 1 (1)                       | 3 (3)                     | 0 (0)              |         |
| Culprit artery, n (%)                  |                    |                             |                           |                    |         |
| Left anterior descending               | 101 (36)           | 55 (39)                     | 31 (31)                   | 15 (43)            | 0.418   |
| Left circumflex                        | 52 (19)            | 30 (21)                     | 17 (17)                   | 5 (14)             |         |
| Right coronary                         | 125 (45)           | 58 (41)                     | 52 (52)                   | 15 (43)            |         |
| Culprit artery TIMI flow grade at initial angiography, n (%) | 0/1 | 204 (73) | 93 (65) | 79 (79) | 32 (91) | 0.007 |
| 2                                      | 48 (17)            | 33 (23)                     | 12 (12)                   | 3 (9)              |         |
| 3                                      | 26 (9)             | 17 (12)                     | 9 (9)                     | 0 (0)              |         |
| Culprit artery TIMI flow grade post-PCI, n (%) | 0/1 | 1 (0) | 1 (1) | 0 (0) | 0 (0) | 0.026 |
| 2                                      | 12 (4)             | 5 (4)                       | 2 (2)                     | 5 (14)             |         |
| 3                                      | 265 (95)           | 137 (96)                    | 98 (98)                   | 30 (86)            |         |

Continued
Thermodilution Waveforms and Infarct Characteristics

Acute and final infarct sizes at 6 months were greatest in the bimodal waveform group (Table 2). Microvascular obstruction and myocardial hemorrhage were associated with thermodilution waveform pattern ($P=0.002$ and 0.004, respectively) (Table 3), and proportionately more patients in the bimodal waveform group were affected (Table 2).

Multivariable Associations of Thermodilution Waveform Type in the Culprit Coronary Artery and Microvascular Infarct Pathology

**Microvascular Obstruction**

In a binary logistic regression model with baseline characteristics, thermodilution waveform status was a multivariable associate of microvascular obstruction revealed by CMR 2 days post-myocardial infarction (Table 4). This relationship was no longer significant when IMR >40 or an IMR (5 per unit) were included.

**Myocardial Hemorrhage**

Thermodilution waveform status was a multivariable associate of myocardial hemorrhage (Table 5), but this relationship was no longer significant when an IMR >40 ($P>0.05$) or an IMR (per 5 unit) ($P>0.05$) was included.

Thermodilution Waveforms and LV Outcomes During Follow-Up

**Changes in LV End-Diastolic Volume**

IMR (5 unit difference) was a multivariable associate of change in LV end-diastolic volume, independent of

### Table 1. Continued

| Characteristics | All Patients n=278 | Narrow Unimodal n=143 (51%) | Wide Unimodal n=100 (36%) | Bimodal n=35 (13%) | $P$ Value |
|----------------|-------------------|-----------------------------|---------------------------|-------------------|-----------|
| TIMI Myocardial Blush Grade | | | | | |
| 0/1 | 78 (28) | 38 (27) | 27 (27) | 13 (37) | 0.436 |
| 2/3 | 200 (72) | 105 (73) | 73 (73) | 22 (63) | |
| Treatment, n (%) | | | | | |
| Aspirin | 277 (100) | 142 (99) | 100 (100) | 35 (100) | 1.000 |
| Clopidogrel | 275 (99) | 141 (99) | 99 (99) | 35 (100) | 1.000 |
| β-Blocker | 266 (96) | 137 (96) | 95 (95) | 34 (97) | 0.861 |
| ACE inhibitor or angiotensin receptor blocker | 275 (99) | 141 (99) | 99 (99) | 35 (100) | 0.769 |
| Blood results on admission | | | | | |
| Troponin I, ng/L, median (Q1-Q3) | 1710 (109–5104) | 1628 (97–3673) | 1762 (111–5245) | 2932 (129–7766) | 0.159 |
| Monocytes, $\times 10^9$/L | 1.1±0.4 | 1.0±0.3 | 1.1±0.4 | 1.3±0.4 | 0.011 |
| NT-proBNP, pg/mL | 1299/1473 | 964±1218 | 1440±1535 | 2344±1848 | 0.006 |

Killip classification of heart failure after acute myocardial infarction: class I, no heart failure; class II, pulmonary rales or crepitations, a third heart sound, and elevated jugular venous pressure; class III, acute pulmonary edema; class IV, cardiogenic shock. ACE indicates angiotensin converting enzyme; BMI, body mass index; IMR, index of microvascular resistance; IQR, interquartile range; NT-proBNP, N-terminal pro b-type natriuretic peptide; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction grade.

### Footnotes

*Data are reported as mean (SD), median (IQR), or N (%) as appropriate. *P* values have been obtained from a *t* test ($t$), Mann-Whitney test, or Fisher test.

1Reperfusion strategy includes primary PCI (n=257 [92%]), rescue PCI (failed thrombolysis; n=14 [5%]), and successful thrombolysis (n=7 [3%]). A diseased artery is defined as a stenosis >50% in a major coronary artery >2.5 mm in diameter.
thermodilution waveform status (regression coefficient [95% confidence interval] = 0.87 [0.11, 1.62], \(P = 0.024\)) (Table S1).

**Changes in LV Ejection Fraction**

Thermodilution waveform status, IMR > 40, and IMR (for a 5-unit change) were not associates of changes in LV ejection fraction (Table S2).

**Thermodilution Waveforms and Longer-Term Health Outcomes**

**All-Cause Death or Heart Failure Hospitalization**

The median duration of follow-up was 1469 days in 278 STEMI patients. During this time, 40 (14.4%) participants died or experienced a heart failure episode. The occurrence of a
bimodal thermodilution waveform was independently associated with all-cause death and heart failure hospitalization (odds ratio [95% confidence interval] = 2.70 [1.10, 6.63]; \( P = 0.031 \)), independent of IMR > 40, ST-segment resolution, and TIMI Myocardial Perfusion grade (Table 6). However, the relationship was not statistically significant (odds ratio [95% confidence interval] = 2.35 [0.90, 6.14]; \( P = 0.080 \)) when infarct size was included in the model (Table 6).

Nineteen (6.8%) patients died during follow-up. IMR alone was not associated with death (Table 6).

**Discussion**

The main findings of our study are these: (1) thermodilution in the culprit coronary artery was straightforward and feasible to perform in a comparatively large number of patients with
acute STEMI, and intraobserver and interobserver variabilities for classification of the waveform morphologies were reasonably high; (2) thermodilution waveform type was associated with IMR. A bimodal waveform was a multivariable associate of microvascular obstruction; however, this relationship was no longer significant when IMR was included (either IMR [for a 5-unit change] or IMR >40); (3) IMR (for a 5-unit change) was an independent predictor of myocardial hemorrhage; (4) a bimodal thermodilution waveform was a multivariable associate of adverse clinical outcomes during follow-up, including after adjustment for IMR >40.

Table 3. Univariable Association Among Thermodilution Waveform, IMR (for a 5-Unit Change), and LV Function and Pathology Revealed on CMR

| Left Ventricular Function and Pathology Revealed on CMR | Microvascular Obstruction | Intramyocardial Hemorrhage | Infarct Size During Follow-Up at 6 Months | Change in LV Ejection Fraction | Change in LV End-Diastolic Volume |
|--------------------------------------------------------|---------------------------|---------------------------|------------------------------------------|-------------------------------|----------------------------------|
| IMR (for a 5-unit change)                              | OR (95% CI)               | OR (95% CI)               | Coefficient (95% CI)                     | Coefficient (95% CI)          | Coefficient (95% CI)            |
| IMR = 0 (yes vs no)                                    | 2.28 (1.34, 3.89)         | 2.26 (1.24, 4.05)         | 1.56 (0.24, 2.88)                        | 0.020                         | 0.244                            |
| IMR > 0 and bimodal                                    | 2.44 (2.63, 49.84)        | 1.50 (1.56, 12.98)        | 1.15 (1.07, 3.38)                        | 0.005                         | 0.004                            |

Thermodilution waveform (reference—narrow unimodal)

| Thermodilution waveform | Wide unimodal | Bimodal | IMR > 40 and bimodal |
|-------------------------|---------------|---------|----------------------|
| OR (95% CI)             | OR (95% CI)   | OR (95% CI) | Coefficient (95% CI) | Coefficient (95% CI) |
| IMR < 0.05             | 1.25 (0.75, 2.10) | 4.38 (1.72, 11.20) | 2.44 (2.63, 49.84) | 1.50 (1.56, 12.98) |
| IMR > 0.05             | 1.35 (0.74, 2.44) | 3.70 (1.52, 8.99) | 1.50 (1.56, 12.98) | 1.15 (1.07, 3.38) |

CI indicates confidence interval; CMR, cardiac magnetic resonance imaging; IMR, index of microvascular resistance; LV, left ventricle; OR, odds ratio.

Taken together, these results indicate that a bimodal waveform is an associate of adverse clinical outcomes post—myocardial infarction and may be useful for risk stratification of STEMI patients immediately after reperfusion therapy. Waveform classification and IMR have relative merits. The waveform classification represents a binary approach to risk stratification, whereas IMR and other indices (such as hyperemic microvascular resistance derived using Doppler) provide a continuous measure of microvascular dysfunction and in this sense may be more informative.

Fearon et al first reported that an IMR >40 measured after angiographically successful primary PCI was an independent predictor of adverse clinical outcome. 12 We previously found

Table 4. Multivariable Associations Between Clinical Characteristics at Presentation, Including Thermodilution Waveforms, and the Occurrence of Microvascular Obstruction 2 Days Later in Patients With Acute STEMI

| Binary Logistic Regression | Odds Ratio (95% CI) | P Value |
|---------------------------|---------------------|---------|
| Bimodal waveform          | 5.29 (1.73, 16.22)  | 0.004   |

ST-segment resolution

| None                      | 2.44 (1.30, 4.57)  | 0.006   |
| Partial                   | 3.54 (1.34, 9.33)  | 0.011   |
| Sex                       | 2.17 (1.13, 4.16)  | 0.020   |
| Previous PCI              | 10.97 (1.03, 116.83) | 0.047 |

Other baseline characteristics included are smokers (P = 0.114), hypertension (P = 0.155), wide unimodal waveform (P = 0.388), hypercholesterolemia (P = 0.390), previous angina (P = 0.405), age, y (P = 0.599), TIMI Myocardial Perfusion Grade post-PCI 2/3 (P = 0.60), BMI, kg/m² (P = 0.615), SBP per 10 mm Hg (P = 0.685), previous MI (P = 0.776), heart rate, bpm (P = 0.819), diabetes mellitus (P = 0.980), symptoms to reperfusion time per 10 minutes (P = 0.084). BMI indicates body mass index; CI, confidence interval; MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-segment—elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction.

Table 5. Multivariable Associations Between Clinical Characteristics at Presentation, Including Thermodilution Waveform, and the Occurrence of Myocardial Hemorrhage 2 Days Later in Patients With Acute STEMI

| Binary Logistic Regression | Odds Ratio (95% CI) | P Value |
|---------------------------|---------------------|---------|
| Smoker                    | 3.93 (1.70, 8.65)   | 0.001   |
| ST-segment resolution—partial | 3.88 (1.36, 11.09) | 0.012   |
| Sex                       | 2.65 (1.20, 5.85)   | 0.016   |
| Bimodal waveform          | 3.45 (1.16, 10.26)  | 0.026   |

Other baseline characteristics included are ST-segment resolution—none (P = 0.066), previous PCI (P = 0.086), symptoms to reperfusion time per 10 minutes (P = 0.171), wide unimodal waveform (P = 0.171), age, y (P = 0.218), hypercholesterolemia (P = 0.254), heart rate, bpm (P = 0.545), previous MI (P = 0.556), hypertension (P = 0.573), systolic blood pressure per 10 mm Hg (P = 0.582), percentage residual stenosis (P = 0.773), BMI (P = 0.860), diabetes mellitus (P = 0.861), previous angina (P = 0.870), TIMI Myocardial Perfusion Grade post-PCI 2/3 (P = 0.976). BMI indicates body mass index; CI, confidence interval; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment—elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction.
Table 6. Association Between Clinical Factors at the Time of Invasive Management, Including the Type of Coronary Thermodilution Waveform, and All-Cause Death or Heart Failure Hospitalization and Death Only After the Index Admission During Longer-Term Follow-Up in 278 STEMI Patients

| Associations                                      | Odd Ratio (95% CI) | P Value |
|--------------------------------------------------|--------------------|---------|
| Univariable associations with all-cause death or heart failure |                    |         |
| Bimodal waveform                                  | 4.01 (1.80, 8.93)  | 0.001   |
| IMR=40 and bimodal waveform                       | 5.77 (2.33, 14.31) | <0.001  |
| IMR (for a 5-unit change)                         | 2.41 (1.22, 4.77)  | 0.012   |
| IMR (for a 5-unit change)                         | 1.07 (1.02, 1.12)  | 0.003   |
| TIMI Myocardial Perfusion Grade 2/3               | 1.67 (0.83, 3.36)  | 0.154   |
| ST-segment resolution~50%                         | 2.52 (1.23, 5.17)  | 0.011   |
| Acute infarct size                                | 1.09 (1.06, 1.12)  | <0.001  |
| Multivariable associations with all-cause death or heart failure |                    |         |
| Model A—bimodal waveform and IMR                 |                    |         |
| Bimodal waveform                                  | 2.46 (0.95, 6.40)  | 0.065   |
| IMR (for a 5-unit change)                         | 1.04 (0.99, 1.10)  | 0.144   |
| ST-segment resolution~50%                         | 1.92 (0.90, 4.10)  | 0.093   |
| TIMI Myocardial Perfusion Grade 2/3               | 1.28 (0.58, 2.85)  | 0.545   |
| Akaike Information Criterion                     | 131.84             |         |
| Model B—bimodal waveform and IMR=40              |                    |         |
| Bimodal waveform                                  | 2.70 (1.10, 6.63)  | 0.031   |
| IMR=40                                           | 1.84 (0.84, 4.03)  | 0.128   |
| ST-segment resolution~50%                         | 1.92 (0.90, 4.10)  | 0.092   |
| TIMI Myocardial Perfusion Grade 2/3               | 1.32 (0.60, 2.90)  | 0.487   |
| Akaike Information Criterion                     | 51.60              |         |
| Model C—bimodal waveform only                    |                    |         |
| Bimodal waveform                                  | 3.32 (1.41, 7.82)  | 0.006   |
| ST-segment resolution~50%                         | 2.01 (0.94, 4.26)  | 0.329   |
| TIMI Myocardial Perfusion Grade 2/3               | 1.47 (0.68, 3.16)  | 0.070   |
| Akaike Information Criterion                     | 33.28              |         |
| Model D—IMR for a 5-unit change only              |                    |         |
| IMR (for a 5-unit change)                         | 1.07 (1.01, 1.12)  | 0.014   |
| ST-segment resolution~50%                         | 2.08 (0.99, 4.38)  | 0.054   |
| TIMI Myocardial Perfusion Grade 2/3               | 1.27 (0.58, 2.78)  | 0.558   |
| Akaike Information Criterion                     | 199.91             |         |
| Model E—IMR=40 only                              |                    |         |
| IMR=40                                           | 2.29 (1.09, 4.81)  | 0.028   |
| ST-segment resolution~50%                         | 2.14 (1.02, 4.49)  | 0.043   |

Median duration of follow-up was 4 years. Minimum to maximum postdischarge censor duration was 1 to 1800 days.

Continuous waveforms were more commonly observed in patients with STEMI only compared with those with STEMI and microvascular obstruction and myocardial hemorrhage, whereas an IMR >40 was most closely associated with all-cause death or heart failure.13 We also observed that IMR was...
associated with the systemic concentration of IL-6 on the first day post-STEMI, reflecting systemic inflammation and vascular injury.13 The current study extends these findings because a bimodal thermodilution waveform was associated with heart failure post–myocardial infarction, systemic inflammation (monocyte count), and circulating concentrations of NT-proBNP early post–myocardial infarction.

Fukunaga et al14 reported that a bimodal thermodilution waveform was independently associated with the presence of microvascular obstruction on CMR, and this was associated with worse mid-term clinical outcomes. They hypothesized that the bimodal thermodilution waveform may be explained by resistance to antegrade flow within the culprit coronary artery due to microvascular destruction.14 IMR derived from a bimodal curve incorporates a mean transit time derived from disordered antegrade coronary flow, potentially even transient retrograde flow, secondary to microvascular dysfunction.33 This scenario calls into question the validity of transit time as a proxy for flow when the thermodilution curve is bimodal. On the other hand, the prognostic associations for IMR in continuous and binary forms are well established. Our observations are in keeping with those of Fukunaga et al14 and suggest that the bimodal thermodilution waveform reflects more severe, persistent microvascular injury and has the potential for immediate risk stratification in the catheterization laboratory. Patients with a bimodal waveform are at risk of adverse outcomes, indicating the need for more intensive therapy and follow-up.

In our study, microvascular obstruction and myocardial hemorrhage were associated with thermodilution waveform pattern, and each pathology was more prevalent in patients with a bimodal morphology; however, this relationship was not independent of other characteristics when assessed in a multivariable regression model. Instead, our results showed that IMR (for a 5-unit change) was a stronger associate of microvascular obstruction and myocardial hemorrhage. Logistic regression analysis showed that bimodal thermodilution waveform status was a stronger predictor of all-cause death and heart failure hospitalization than IMR. When infarct size measured on CMR 2 days later was included, the prognostic significance of IMR was lost. IMR (for a 5-unit change) was the only independent predictor of infarct size during follow-up on multivariate analyses (Table S3). The associations among IMR (ordinal value), thermodilution waveform status (bimodal), and myocardial hemorrhage, reflecting severe irreversible vascular damage within the infarct zone, provide a pathophysiological basis for adverse health outcomes in the longer term.

Our study extends that of Fukunaga et al.14 Some of the differences in the results may relate to differences in the patient populations, sample size, CMR methods used, and duration of follow-up. For example, Fukunaga et al14 excluded STEMI patients presenting with Killip class III/IV acute heart failure and left mainstem culprit lesions.14 The only exclusion criterion in our study was a contraindication to contrast MRI. In addition, our study was 3 times larger and had substantially longer follow-up (median of 1469 days versus 6 months). The intra- and interobserver coefficients reported in our study are lower than those reported by Fukunaga et al,14 implying that development of an automated algorithm may enhance precision and accuracy in the clinic.

Similar to IMR (for a 5-unit change), a bimodal thermodilution waveform is a stronger predictor of adverse clinical outcome than ST-segment resolution on ECG, or angiographic flow grades and may be useful for risk stratification of STEMI patients immediately after reperfusion. IMR is independently associated with microvascular obstruction and myocardial hemorrhage, and because it is a continuous value, it holds the potential to quantify the efficacy of novel reperfusion therapies designed to restore microvascular perfusion and limit infarct size. This possibility is currently being assessed in a randomized, controlled phase 2 clinical trial of low-dose alteplase (10 and 20 mg) or placebo directly administered into the culprit coronary artery after reperfusion but before stenting (T-TIME ClinicalTrials.gov, Identifier: NCT02257294).

Conclusion

Our study adds to previous investigations using coronary thermodilution for risk assessment in patients with acute STEMI. We conclude that a bimodal thermodilution waveform identifies high-risk patients who may benefit from more intensive follow-up and medical therapy.

Limitations

Our study took place in a single center, and further research in other hospitals is warranted. Only 13% of patients had a bimodal waveform, limiting to some extent its clinical impact. The waveform classification was undertaken post hoc using a core laboratory approach. The diagnostic accuracy of clinician-reported waveform classification during real-world practice merits further assessment.

Acknowledgments

We thank all the patients who agreed to participate in the study, staff in the Cardiology and Radiology Departments in the Golden Jubilee National Hospital. We acknowledge biostatistical support from Dr Caroline Haig.

Sources of Funding

This work was supported by the British Heart Foundation Centre of Research Excellence Award (RE/13/5/30177), the Fundación BBVA, and the Fondo de Investigación Sanitaria (PI17/01675).
Britain’s National Health Service, and the Chief Scientist Office. Professor Berry was supported by a Senior Fellowship from the Scottish Funding Council.

Disclosures

Siemens provided health-related work-in-progress imaging methods. Based on an institutional agreement with the University of Glasgow, Professor Berry has acted as a consultant to Abbott Vascular. Professor Oldroyd has acted as consultant to Abbott Vascular. These companies had no involvement in the current research or the article. The remaining authors have no disclosures to report.

References

1. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Faxon DC, Fihn SD, Forouzanfar MH, Hall WJ, et al. 2013 ACCF/AHA guideline for the diagnosis and management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e392–e425.

2. McGeoch R, Watkins S, Berry C, Steedman T, Davie A, Byrne J, Hills S, Lindsay M, Robb S, Dargie H, Oldroyd K. The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Inter. 2010;3:715–722.

3. Carrick D, Haig C, Ahmed N, McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay M, Davie A, Mahmoud A, Mordi I, Rauhhalammi S, Satter N, Welsh P, Radjenovich A, Ford I, Oldroyd K, Berry C. Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. Circ Cardiovasc Imaging. 2016;9:e004148.

4. Frohlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J. 2013;34:1714–1722.

5. Carrick D, Haig C, Rauhhalammi S, Ahmed N, Mordi I, McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay M, Davie A, Mahmoud A, Satter N, Welsh P, Radjenovich A, Ford I, Oldroyd K, Berry C. Myocardial hemorrhage after acute reperfused ST-segment elevation myocardial infarction survivors. Eur Heart J. 2016;37:1044–1059.

6. de Waha S, Desch S, Eitel I, Fuernau G, Zachau J, Leuschner A, Gutberlet M, Schuler G, Thiele H. Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction: a comparison with traditional prognostic markers. Eur Heart J. 2010;31:2660–2668.

7. van ’t Hof AW, Liem A, Suryapranata H, Hoontje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwilte Myocardial Infarction Study Group. Circulation. 1998;97:2302–2306.

8. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125–130.

9. Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MB, Umans VA, Algra PR, Twisk JW, van Rossum AC. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol. 2008;52:181–189.

10. Eitel I, de Waha S, Wohrle J, Fuernau G, Lurz P, Pauschinger M, Desch S, Schuler G, Thiele H. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014;64:1217–1226.

11. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Casper JH, Cerqueira MD, Charron DP, Conte MS, Cremona JP, Creel F, Evangelista A, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst G, Vranckx P, Widimsky P; ESC Scientific Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–177.

12. Fearon WF, Low AF, Yong AS, McGeoch R, Berry C, Shah MG, Ho MY, Kim HS, Loh JP, Oldroyd KG. Prognostic value of the index of microcirculatory resistance measured after primary percutaneous coronary intervention. Circulation. 2015;132:2436–2441.

13. Carrick D, Haig C, Ahmed N, Carberry J, Teng VYM, McEntegart M, Petrie MC, Eteiba H, Lindsay M, Hood S, Watkins S, Davie A, Mahmoud A, Mordi I, Ford I, Radjenovich A, Oldroyd KG, Berry C. Comparative prognostic utility of indexes of microvascular function alone or in combination in patients with an acute ST-segment-elevation myocardial infarction. Circulation. 2016;134:1833–1847.

14. Fukunaga M, Fuji K, Kawasaki D, Sawada H, Miki K, Tamaru H, Imamura T, Iwasaki T, Nakata T, Shibuya M, Akahori H, Masutani M, Kobayashi K, Ohyanagi M, Masuyama T. Thermodilution-derived coronary blood flow pattern immediately after coronary intervention as a predictor of microcirculatory damage and midterm clinical outcomes in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Inter, 2014;7:149–155.

15. Kramer CM, Barkhausen J, Flam S, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91.

16. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4:150–156.

17. Ghugre NR, Ramanan V, Pop M, Yang Y, Barry J, Ong B, Connolly KA, Dick AJ, Wright GA. Quantitative tracking of edema, hemorrhage, and microvascular obstruction in subacute myocardial infarction in a porcine model by MRI. Magn Reson Med. 2011;66:1129–1141.

18. Kandler D, Lucke C, Grothoff M, Andres C, Lehmkhul N, Nitzsche S, Riese F, Mende M, de Waah S, Desch S, Lurz P, Eitel I, Gutberlet M. The relation between hypointense core, microvascular obstruction and intramyocardial haemorrhage in acute reperfused myocardial infarction assessed by cardiac magnetic resonance imaging. Eur Radiol. 2014;24:3277–3288.

19. O’Regan DP, Arifi B, Neuwirth C, Tan Y, Durghel G, Cook SA. Assessment of severe reperfusion injury with 2T* MRI in patients with acute myocardial infarction. Heart. 2010;96:1885–1891.

20. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–2179.

21. Gir S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV, Simonetti OP. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson. 2009;11:56.

22. Verhaert D, Thavendiranathan P, Gir S, Mihai G, Rajagopalan S, Simonetti OP, Raman SV. Direct T2 quantification of myocardial edema in acute ischemic injury. JACC Cardiovasc Imaging. 2011;4:269–278.

23. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, Thiele H. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol. 2010;55:2470–2479.

24. Berry C, Kellman P, Mancini C, Chen MY, Bandettini WP, Lowrey T, Hsu LY, Aletras AH, Arai AE. Magnetic resonance imaging delineates the ischemic area at risk and myocardial salvage in patients with acute myocardial infarction. Circ Cardiovasc Imaging. 2014;7:527–535.

25. Payne AR, Casey M, McClure J, McGeoch R, Murphy A, Woodward R, Saul A, Bi X, Zuehlsdorff S, Oldroyd KG, Tzemos N, Berry C. Bright-blood T2-weighted MRI has higher diagnostic accuracy than dark-blood short tau inversion recovery MRI for detection of acute infarction and for assessment of the ischemic area at risk and myocardial salvage. Circ Cardiovasc Imaging. 2011;4:210–219.

26. Francone M, Bucciarelli-Ducci C, Carbone I, Canali E, Scardala R, Calabrese FA, Sardella G, Bogaert J, Agati L, Aletras AH, Arai AE. Magnetic resonance delineates the ischemic area at risk and myocardial salvage in patients with acute myocardial infarction. Circ Cardiovasc Imaging. 2011;4:210–219.

27. Payne AR, Berry C, Doolin O, McEntegart M, Petrie MC, Lindsay MM, Hood S, Carrick D, Tzemos N, Weale P, McClam B, Foster J, Ford I, Oldroyd KG. Microvascular resistance predicts myocardial salvage and infarct size after emergency primary percutaneous coronary intervention. J Am Coll Cardiol. 2009;54:2145–2153.
characteristics in ST-elevation myocardial infarction. J Am Heart Assoc. 2012;1:e002246. DOI: 10.1161/JAHA.112.002246.

28. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducroq G, Fernandez-Avilés F, Gerhlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knudt J, Lenzen MJ, Mahaffey KW, Valgimiggi M, van’t Hof A, Widimsky P, Zahger D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–2619.

29. TIMI-Study-Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985;312:932–936.

30. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–888.

31. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. Circulation. 2012;126:2020–2035.

32. Hicks KA, Tcheng JE, Bokurt B, Chaitman BR, Cutilip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL; American College of Cardiology; American Heart Association. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Nucl Cardiol. 2015;22:1041–1144.

33. Meier P, Zierler KL. On the theory of the indicator-dilution method for measurement of blood flow and volume. J Appl Physiol. 1954;6:731–744.
Supplemental Material
Supplemental Methods

Setting and study populations

STEMI patients

Screening, enrolment, and data collection were prospectively performed by cardiologists in the cardiac catheterization laboratories of the Golden Jubilee National Hospital, Glasgow, United Kingdom. This hospital is a regional referral centre for primary and rescue percutaneous coronary intervention (PCI). The hospital provides clinical services for a population of 2.2 million. A screening log was recorded, including patients who did not participate in the cohort study. Patients were invited to undergo cardiac magnetic resonance imaging (CMR) 2 days and 6 months after hospital admission (1)(2).

Coronary angiogram acquisition

Coronary angiograms were acquired during usual care with cardiac catheter laboratory X-ray (Innova®) and IT equipment (Centricity®) made by GE Healthcare.

Percutaneous coronary intervention

Consecutive admissions with acute STEMI referred for emergency percutaneous coronary intervention (PCI) were screened for the inclusion and exclusion criteria. During ambulance transfer to the hospital, the patients received 300 mg of aspirin, 600 mg of clopidogrel and 5000 IU of unfractionated heparin (3, 4). The initial primary PCI procedure was performed using radial artery access. A conventional approach to
primary PCI was adopted in line with usual care in our hospital (3, 4). Conventional bare metal and drug eluting stents were used in line with guideline recommendations and clinical judgement. The standard transcatheter approach for reperfusion involves minimal intervention with aspiration thrombectomy only or minimal balloon angioplasty (e.g. a compliant balloon sized according to the reference vessel diameter and inflated at 4-6 atmospheres 1-2 times). During PCI, glycoprotein IIbIIIa inhibitor therapy was initiated with high dose tirofiban (25 μg/kg/bolus) followed by an intravenous infusion of 0.15 μg/kg/min for 12 hours, according to clinical judgement and indications for bail-out therapy (3, 4). No reflow was treated according to contemporary standards of care with intra-coronary nitrate (i.e. 200 μg) and adenosine (i.e. 30 – 60 μg) (3, 4), as clinically appropriate. In patients with multivessel coronary disease, multivessel PCI was not recommended, in line with clinical guidelines (3, 4). The subsequent management of these patients was symptom-guided.

**Measurement of IMR and CFR at the end of PCI**

We adopted a thermodilution technique rather than Doppler, in order to implement a method that is potentially transferable to routine clinical practice. The Doppler measurements are more time-consuming, require considerable experience, may be less reproducible (5) and the guidewire is typically more expensive. The Doppler method less transferrable to every-day practice than the thermodilution method.

A coronary pressure- and temperature-sensitive guidewire (St Jude Medical, Uppsala, Sweden) was used to measure coronary flow reserve (CFR) and the index of microvascular resistance (IMR) in the culprit coronary artery at the end of primary or rescue PCI. The guidewire was calibrated outside the body, equalized with aortic
pressure at the ostium of the guide catheter and then advanced to the distal third of the culprit artery. Coronary flow reserve is defined as the mean transit time at rest divided by the mean transit time during hyperemia.

IMR is defined as the distal coronary pressure multiplied by the mean transit time of a 3 ml bolus of saline at room temperature during maximal coronary hyperemia, measured simultaneously (mmHg x s, or units) (6-8).

Hyperemia was induced by 140 µ/kg/min of intravenous adenosine preceded by a 2 ml intracoronary bolus of 200 µg of nitrate. The mean aortic and distal coronary pressures were recorded during maximal hyperemia. We have previously assessed the repeatability of IMR using duplicate measurements 5 minutes apart in a subset of 12 consecutive patients (8).

**Visual assessment of coronary thermodilution waveforms**

When 3ml of room temperature saline was pushed in the hyperaemic coronary artery, the temperature inside the coronary artery dropped, and the change in temperature was detected by the thermistor at the end of the guidewire and recorded on Radiview 2.2 software in a computer in the form of a graph (change in temperature against time). 3 bolus of 3ml saline were used, producing 3 curves known as the thermodilution curves on the graph. We carried out the visual assessment of the coronary blood flow pattern of the thermodilution curve using similar method described in *Fukunaga et al.* *Fukunaga et’s paper* (9). The thermodilution waveforms were classified into 3 groups: bimodal, sharp unimodal, and wide unimodal. All bimodal waveforms were identified. The transit times from the beginning of drop to the peak drop in temperature of all the
unimodal curves are measured, and the mean was calculated (0.42±0.15s). Narrow unimodal profile has a transit time less than the mean (0.42s) and wide unimodal profile has a transit time more than the mean (0.42s). Narrow unimodal waveform was defined as: Sharp decrease of temperature, followed by rapid return to baseline temperature with a time from the beginning of drop to the peak drop in temperature is less than 0.42s. Wide Unimodal waveform was defined as: Decrease of temperature at the beginning, followed by gradual return to the baseline temperature. Time from beginning of drop to peak drop in temperature is more than 0.42s. Bimodal waveform was defined as: waveform with two distinct nadirs (defined as the second nadir having a valley deeper than 20% of the peak temperature drop.

**Angiographic analysis**

**Coronary artery anatomy**

The coronary anatomy and disease characteristics of the study participants were described based on the clinical reports of the attending cardiologist. Coronary dominance were assigned as left, right or balanced according to the origin of the posterior descending coronary artery.

**Coronary artery disease severity**

Quantitative coronary analysis (QCA) of the culprit vessel was performed by two trained observers (J.C., V.Y.T.M) using standard methods (Centricity®, GE Healthcare, Pollards Wood, UK). All coronary angiograms were analysed on a single image analysis software platform using de-identified images. Automatic edge detection algorithms were used to determine the vessel contours by assessing brightness along scan lines perpendicular to the vessel center. Image analysis was performed by two
experienced observers supervised by an expert physician, all of whom were blinded to the other study data. End-diastolic frames were used to assess disease severity using angulations reveal the stenosis at its most severe degree with minimal foreshortening and branch overlap. The coronary artery segments in the culprit artery included all those with a reference diameter ≥1.5 mm.

Definitions

**TIMI flow grade**

Coronary blood flow can be described based on the visual assessment of coronary blood flow revealed by contrast injection into the coronary arteries (3, 4, 10).

| TIMI Coronary Flow Grade | Description                                      |
|--------------------------|--------------------------------------------------|
| 0                        | No flow                                          |
| 1                        | Minimal flow past obstruction                    |
| 2                        | Slow (but complete) filling and slow clearance   |
| 3                        | Normal flow and clearance                        |

**Myocardial perfusion**

Angiographic evidence of myocardial perfusion will be evaluated using the TIMI myocardial perfusion grade (TMP) at the end of the PCI procedure (11).

| Grade | Description                                                                 |
|-------|-----------------------------------------------------------------------------|
| 0     | No myocardial blush                                                         |
| 1     | Minimal blush and very slow clearing (e.g. present at beginning of next cine) |
Good blush with slow clearing of myocardial contrast (present at end of cine but gone at beginning of next)

Good blush and normal clearing (ie. gone by end of cine)

Assessment by corrected Thrombolysis In Myocardial Infarction Frame Count

Corrected TIMI frame count (cTFC) was calculated as the number of frames for dye to reach a standardised distal landmark in each angiographic territory. The first frame taken for the measurement was the frame in which dye touched both borders of the coronary artery in question and moved forward with at least 70% of the vessel lumen opacified. The standardised distal landmarks were taken as the first branch of the postero-lateral artery for the right coronary artery, the most distal branch of the obtuse marginal for the circumflex, and the distal bifurcation of the left anterior descending (LAD) coronary artery. The number of frames from the first frame to the last frame when the dye entered the standardised distal landmark was counted. A standard image acquisition speed of 30 frames per second was used. The correction factor used to account for the increased length of the LAD compared to the right and circumflex arteries was 1.7 thereby giving a “corrected TIMI frame count”.

CMR acquisition and analyses

We used CMR to provide reference data on LV function, pathology and surrogate outcomes, independent of the invasive tests.

CMR acquisition

CMR was performed on a Siemens MAGNETOM Avanto (Erlangen, Germany) 1.5-Tesla scanner with a 12-element phased array cardiac surface coil. T2 maps were
acquired in contiguous short axis slices covering the whole ventricle, using an investigational prototype T2-prepared (T2P) TrueFisp sequence (12, 13). Typical imaging parameters were: bandwidth ~947 Hz/pixel; flip angle 70°; T2 preparations: 0 ms, 24 ms, and 55 ms respectively; matrix 160 x 105 pixels; spatial resolution 2.6 x 2.1 x 8.0 mm; slice thickness 8 mm.

T2*-maps were obtained using an investigational prototype T2* map sequence acquired in 3 short-axis slices (basal, mid and apical). Typical imaging parameters were: bandwidth ~814 (x8) Hz/pixel; flip angle 18°; matrix 256x115; spatial resolution 2.6 x 1.6 x 10 mm; slice thickness 8 mm.

In order to assess early microvascular obstruction, early gadolinium enhancement imaging was acquired 1, 3, 5 and 7 minutes post-contrast injection using a TrueFISP readout and fixed inversion time (TI) of 440 ms. Late gadolinium enhancement images covering the entire LV were acquired 10-15 minutes after intravenous injection of 0.15 mmol/kg of gadoterate meglumine (Gd²⁺-DOTA, Dotarem, Guebert S.A.) using segmented phase-sensitive inversion recovery (PSIR) turbo fast low-angle shot (14). Microvascular obstruction was defined as a dark zone on early delayed enhancement imaging 1, 3, 5 and 7 minutes post-contrast injection and within an area of late gadolinium enhancement. Typical imaging parameters were: matrix = 192 x 256, flip angle = 25°, TE = 3.36 ms, bandwidth = 130 Hz/pixel, echo spacing = 8.7ms and trigger pulse = 2. The voxel size was 1.8 x 1.3 x 8 mm³. Inversion times were individually adjusted to optimize nulling of apparently normal myocardium (typical values, 200 to 300 ms).
MR image analyses

The images were analysed on a Siemens work-station by observers with at least 3 years CMR experience (N.A., D.C., I.M). All of the images were reviewed by experienced CMR cardiologists (C.B., N.T.). LV dimensions, volumes and ejection fraction were quantified using computer assisted planimetry (syngo MR®, Siemens Healthcare, Erlangen, Germany). All scan acquisitions were spatially co-registered.

*T2 and T2* – standardized measurements in myocardial regions of interest*

LV contours were delineated with computer assisted planimetry on the raw T2* image and the last corresponding T2 raw image, with echo time of 55 ms (15). Contours were then copied onto the colour-encoded spatially co-registered maps and corrected when necessary by consulting the SSFP cine images. Apical segments were not included because of partial volume effects. Particular care was taken to delineate regions of interest with adequate margins of separation from tissue interfaces prone to partial volume averaging such as between myocardium and blood. Each T2/ T2* map image was visually assessed for the presence of artefacts relating to susceptibility effects or cardio-respiratory motion. Each map was evaluated against the original images. When artefacts occurred, the affected segments were not included in the analysis.

T2/ T2* values were segmented spatially and regions of interest were defined as (1) remote myocardium, (2) injured myocardium and (3) infarct core. The regions-of-interest were planimetered to include the entire area of interest with distinct margins of separation from tissue interfaces to exclude partial volume averaging. The remote myocardial region-of-interest was defined as myocardium 180° from the affected zone with no visible evidence of infarction, oedema or wall motion abnormalities (assessed by inspecting corresponding contrast enhanced T1-weighted, T2-weighted and cine images, respectively). The infarct zone region-of-interest was defined as myocardium
with pixel values (T2) >2 SD from remote myocardium on T2-weighted CMR (12, 13). The infarct core was defined as an area in the center of the infarct territory having a mean T2/T2* value of at least 2 standard deviations (SDs) below the T2/T2* value of the periphery of the area-at-risk.

In healthy volunteers, the mid-ventricular T2/T2* map was segmented into 6 equal segments, using the anterior right ventricular-LV insertion point as the reference point (2). T2/T2* was measured in each of these segments, and regions-of-interest were planimetered distinct and separate from blood-pool and tissue interfaces. These segmental values were also averaged to provide one value per subject. Results are presented as average values for segments and slices.

**Infarct definition and size**

The presence of acute infarction was established based on abnormalities in cine wall motion, rest first-pass myocardial perfusion, and delayed-enhancement imaging. In addition, supporting changes on the ECG and coronary angiogram were also required. Acute infarction was considered present only if late gadolinium enhancement was confirmed on both the axial and long axis acquisitions. The myocardial mass of late gadolinium (grams) was quantified using computer assisted planimetry and the territory of infarction was delineated using a signal intensity threshold of >5 standard deviations above a remote reference region and expressed as a percentage of total LV mass (5). Infarct regions with evidence of microvascular obstruction were included within the infarct area and the area of microvascular obstruction was assessed separately and also expressed as a percentage of total LV mass. The measurements of infarct size were performed by I.M. and N.A.
Microvascular obstruction

Microvascular obstruction was defined as a dark zone on EGE imaging 1, 3, 5 and 7 minutes post-contrast injection that remained present within an area of late gadolinium enhancement at 15 minutes. Identification of microvascular obstruction was performed independently by I.M. and N.A.

Myocardial hemorrhage

Myocardial haemorrhage was scored visually. On the T2* maps, a region of reduced signal intensity within the infarcted area, with a T2* value of <20 ms (16-19), was considered to confirm the presence of myocardial haemorrhage.

Myocardial edema

The extent of myocardial oedema was defined as LV myocardium with pixel values (T1/T2) >2 standard deviations from remote myocardium (12, 13, 20-23).

Myocardial salvage

Myocardial salvage was calculated by subtraction of percent infarct size from percent area-at-risk (8, 20, 23). The myocardial salvage index was calculated by dividing the myocardial salvage area by the initial area-at-risk.

Adverse remodeling

Adverse remodelling was defined as an increase in LV end-diastolic volume ≥ 20% at 6 months from baseline (24).

Reference ranges

Reference ranges used in the laboratory were 105 – 215 g for LV mass in men, 70 – 170 g for LV mass in women, 77 – 195 ml for LV end-diastolic volume in men, 52 –
141 ml for LV end-diastolic volume in women, 19 – 72 ml for LV end-systolic volume in men and 13 – 51 ml for LV end-systolic volume in women.

**Electrocardiogram**

A 12 lead electrocardiogram (ECG) was obtained before coronary reperfusion and 60 minutes afterwards with Mac-Lab® technology (GE Healthcare) in the catheter laboratory and a MAC 5500 HD recorder (GE Healthcare) in the Coronary Care Unit. The ECGs were acquired by trained cardiology staff. The ECGs were de-identified and transferred to the local ECG management system. The ECGs were then analysed by the University of Glasgow ECG Core Laboratory which is certified to ISO 9001: 2008 standards as a UKAS Accredited Organization.

The extent of ST-segment resolution on the ECG assessed 60 minutes after reperfusion compared to the baseline ECG before reperfusion (3) was expressed as complete (≥70%), incomplete (30% to < 70%) or none (≤30%). ECG evidence of reperfusion injury was taken as persistence of ST segment elevation resolution post-procedure, and specifically ≤30% ST-segment resolution post-PCI.

**Biochemical and hematologic measurement of inflammation**

Serial systemic blood sample were obtained immediately after reperfusion in the cardiac catheterization laboratory, and subsequently between 0600 - 0700 hrs each day during the initial in-patient stay in the Coronary Care Unit. C-reactive protein (CRP) was measured in an NHS hospital biochemistry laboratory using a particle enhanced immunoturbimetric assay method (Cobras C501, Roche), and the manufacturers
calibrators and quality control material, as a biochemical measure of inflammation. The high sensitive assay CRP measuring range is 0.1-250 mg/L. The expected CRP values in a healthy adult are < 5 mg/L, and the reference range in our hospital is 0 - 10 mg/L. A blood sample was routinely obtained in the cardiac catheter laboratory immediately following revascularization and then again at 0700 hrs on the first and second days after admission to hospital.

**Haematological measurement of inflammation**

Leucocyte count and leucocyte sub-populations were measured as a hematologic measure of inflammation using sheath flow technology incorporating semi-conductor laser beam, forward and side scattered light (Sysmex XT200i and XT1800i for white blood cell and differential white blood cell counts, respectively). The linearity ranges for white blood cells was 0.00-440.0 x10(9) /L. The following are the normal ranges for full blood count parameters:

| Parameter         | MALE           | FEMALE         |
|-------------------|----------------|----------------|
| WBC x 10^9/L      | 4.0 - 11.0     | 4.0 - 11.0     |
| RBC x 10^12/L     | 4.50 - 6.50    | 3.80 - 5.80    |
| Hgb g/L           | 130 – 180      | 115 - 165      |
| HCT L/L           | 0.400 - 0.540  | 0.370 - 0.470  |
| MCV fL            | 78 – 99        | 78 - 99        |
| MCH Pg             | 27.0 - 32.0    | 27.0 - 32.0    |
| MCHC g/L          | 310 – 360      | 310 - 360      |
| Cell Type            | Lower Limit | Upper Limit |
|----------------------|-------------|-------------|
| PLATELETS x 10^9/L   | 150 – 400   | 150 - 400   |
| NEUTROPHILS x 10^9/L | 2.5 - 7.5   | 2.5 - 7.5   |
| LYMPHOCYTES x 10^9/L | 1.5 - 4.0   | 1.5 - 4.0   |
| MONOCYTES x 10^9/L   | 0.2 - 0.8   | 0.2 - 0.8   |
| EOSINOPHILS x 10^9/L | 0.0 - 0.4   | 0.0 - 0.4   |
| BASOPHILS x 10^9/L   | 0.01 - 0.10 | 0.01 - 0.10 |

A blood sample was routinely obtained in the cardiac catheter laboratory, immediately following revascularization and then again at 0700 on the first and second days after admission to hospital.

**Pre-specified health outcomes**

We pre-specified adverse health outcomes that are pathophysiologically linked with STEMI. The primary composite outcome was (1) all-cause death or first heart failure event following the initial hospitalization (Supplementary Methods).

Research staff screened for events from enrolment by checking the medical records and by contacting patients and their primary and secondary care physicians, as appropriate with no loss to follow-up (Figure 2). Each serious adverse event (SAE) was reviewed by a cardiologist who was independent of the research team and blinded to all of the clinical and CMR data. The SAEs were defined according to standard guidelines and categorized as having occurred either during the index admission or post-discharge. All study participants were followed-up for a minimum of 18 months after discharge. The median duration of follow-up was of 1339 days (minimum-maximum post-discharge censor duration (range) 1-1800 days).
Statistics

Statistical analysis

Categorical variables are expressed as the number and percentage of patients. Most continuous variables followed a normal distribution and are therefore presented as means together with standard deviation. Those variables that did not follow a normal distribution are presented as medians with interquartile range. Differences in continuous variables between groups were assessed by the Student’s t-test or ANOVA for continuous data with normal distribution, otherwise the nonparametric Mann-Whitney test or Kruskal-Wallis H test. Differences in categorical variables between groups were assessed using a Fisher’s test.

Two raters assessed the thermodilution waveforms of 20 subjects randomly selected from the whole cohort. Inter-rater reliability for the visual assessment of thermodilution waveforms was assessed using weighted Cohen’s kappa.

Univariable and multivariable associations are assessed using binary logistic regression or linear regression where appropriate. The likelihood ratio test was used to compare the binary logistic and linear regression models with bimodal thermodilution waveform, IMR (for a 5 unit change) or an IMR>40. A p-value <0.05 favours including the variable in the model.

All p-values are 2-sided and a p-value > 0.05 indicates the absence of a statistically significant effect. Statistical analyses were performed using SPSS version 22.
**Trial Management**

The study was conducted in line with Guidelines for Good Clinical Practice (GCP) in Clinical Trials. [http://www.mrc.ac.uk/documents/pdf/good-clinical-practice-in-clinical-trials/](http://www.mrc.ac.uk/documents/pdf/good-clinical-practice-in-clinical-trials/)

Trial management included a Trial Management Group, and an independent Clinical Trials Unit. Day to day study activity was coordinated by the Trial Management Group who was responsible to the Sponsor which was responsible for overall governance and that the trial was conducted according to GCP standards.

Clinical events were assessed and validated by an independent cardiologist (A.M.) who had access to relevant source clinical data. This cardiologist followed an agreed charter and he was blinded to all of the other clinical data.
Table S1. Multivariable associations between clinical characteristics at presentation, including thermodilution waveforms, IMR (for a 5 unit change), and the change in left ventricular end-diastolic volume at six months in patients with acute STEMI.

| Association                                      | Coefficient (95% CI) | p value |
|--------------------------------------------------|----------------------|---------|
| LV end-diastolic volume at baseline, ml          | -0.05 (-0.18, 0.07)  | 0.404   |
| IMR (for a 5 unit change)                        | 0.87 (0.11, 1.62)    | 0.024   |
| Diabetes mellitus                                | -12.17 (-23.48, -0.86) | 0.035   |
| Sex                                              | 9.30 (0.29, 18.31)   | 0.043   |
| Bimodal waveform                                 | -3.44 (-16.60, 9.73) | 0.607   |

**Akaike Information Criterion**

With waveform only

| Association                                      | Coefficient (95% CI) | p value |
|--------------------------------------------------|----------------------|---------|
| Diabetes mellitus                                | -12.40 (-23.83, -0.98) | 0.033   |

**Akaike Information Criterion**

1506.01

With IMR only

| Association                                      | Coefficient (95% CI) | p value |
|--------------------------------------------------|----------------------|---------|
| IMR (for a 5 unit change)                        | 0.80 (0.16, 1.45)    | 0.015   |
| Sex                                              | 9.47 (0.50, 18.43)   | 0.039   |
| Diabetes mellitus                                | -11.79 (-23.00, -0.59) | 0.039   |

**Akaike Information Criterion**

1498.86

IMR= index of microvascular resistance. Other variable included are Hypertension (P=0.084), Smoker (P=0.169), Hypercholesterolemia (P=0.205), Heart rate, bmp (P=0.451), Previous Angina (P=0.489), TIMI blush grade post-PCI 2/3 (P=0.489), Age, years (P=0.515), ST segment resolution- none (P=0.521), Percentage Residual Stenosis (P=0.652), SBP, per 10mmHg (P=0.680), Previous MI (P=0.737), BMI, kg/m² (P=0.815), ST segment resolution- partial (P=0.845), Symptoms to reperfusion time per 10 min (P=0.861), Wide unimodal waveform (P=0.884), Previous PCI (P=0.895).
Table S2. Multivariable associations between clinical characteristics at presentation, including thermodilution waveform, IMR (for a 5 unit change), and the change in left ventricular ejection fraction at six months in patients with acute STEMI.

| Association                                      | Coefficient (95% CI)       | p value  |
|--------------------------------------------------|----------------------------|----------|
| LV ejection fraction at baseline, %              | -0.37 (-0.48, -0.26)      | <0.001   |
| Previous MI                                      | -6.13 (-10.74, -1.51)     | 0.01     |
| TIMI blush grade post-PCI 2/3                    | 2.13 (0.07, 4.19)         | 0.043    |
| IMR (for a 5 unit change)                        | -0.12 (-0.32, 0.07)       | 0.216    |
| Bimodal waveform                                 | -2.07 (-5.43, 1.28)       | 0.225    |

**Akaike Information Criterion**  880.95

**With waveform only**

| Association                                      | Coefficient (95% CI)       | p value  |
|--------------------------------------------------|----------------------------|----------|
| Bimodal waveform                                 | -3.04 (-6.03, -0.05)       | 0.046    |
| Previous MI                                      | -6.29 (-10.90, -1.67)      | 0.008    |
| TIMI blush grade post-PCI 2/3                    | 2.44 (0.43, 4.44)          | 0.018    |
| LV ejection fraction at baseline, %              | -0.35 (-0.46, -0.25)       | <0.001   |

**Akaike Information Criterion**  880.65

**With IMR only**

| Association                                      | Coefficient (95% CI)       | p value  |
|--------------------------------------------------|----------------------------|----------|
| IMR (for a 5 unit change)                        | -0.17 (-0.34, -0.01)       | 0.044    |
| Previous MI                                      | -5.87 (-10.44, -1.30)      | 0.012    |
| TIMI blush grade post-PCI 2/3                    | 2.07 (0.03, 4.11)          | 0.047    |
| LV ejection fraction at baseline, %              | -0.36 (-0.47, -0.26)       | <0.001   |

**Akaike Information Criterion**  878.64

IMR = index of microvascular resistance, MI= myocardial infarction, TIMI= thrombolysis in myocardial infarction. Other variables included are Hypertension.
(P=0.118), Smoker (P=0.143), Previous PCI (P=0.302), Sex (P=0.312), Age, years (P=0.313), Previous angina (P=0.414), Percentage residual stenosis (P=0.420), ST segment resolution- None (P=0.485), Hypercholesterolemia (P=0.567), Symptoms to reperfusion time per 10 min (P=0.568), ST segment resolution- Partial (P=0.582), BMI, kg/m² (P=0.730), Wide unimodal waveform (P=0.761), Systolic blood pressure per 10mmHg (P=0.776), Heart rate, bmp (P=0.817), Diabetes mellitus (P=0.931).
Table S3. Multivariable associations between clinical characteristics at presentation, including thermodilution waveforms, IMR (for a 5 unit change), and infarct size at six months later in patients with acute STEMI.

| Association                                      | Coefficient (95% CI) | p value |
|--------------------------------------------------|----------------------|---------|
| Infarct size at baseline, %                      | 0.66 (0.61, 0.71)    | <0.001  |
| Previous MI                                      | 5.55 (2.32, 8.77)    | 0.001   |
| Smoker                                           | 1.68 (0.31, 3.05)    | 0.017   |
| IMR (for a 5 unit change)                        | 0.14 (0.01, 0.27)    | 0.031   |
| TIMI blush grade post-PCI 2/3                    | -1.26 (-2.64, 0.11)  | 0.072   |
| Wide unimodal waveform                           | 1.22 (-0.15, 2.69)   | 0.079   |
| Bimodal waveform                                 | -0.11 (-2.31, 2.09)  | 0.922   |
| Akaike Information Criterion                     |                      |         |

With waveform only

| Association                                      | Coefficient (95% CI) | p value |
|--------------------------------------------------|----------------------|---------|
| Wide unimodal waveform                           | 1.79 (0.51, 3.07)    | 0.006   |
| Smoker                                           | 1.64 (0.25, 3.02)    | 0.021   |
| Previous MI                                      | 5.73 (2.48, 8.98)    | 0.001   |
| TIMI blush grade post-PCI 2/3                    | -1.68 (-3.01, -0.34) | 0.014   |
| Infarct size at baseline, %                      | 0.68 (0.63, 0.73)    | <0.001  |
| Akaike Information Criterion                     |                      | 701.87  |

With IMR only

| Association                                      | Coefficient (95% CI) | p value |
|--------------------------------------------------|----------------------|---------|
| IMR (for a 5 unit change)                        | 0.16 (0.05, 0.27)    | 0.004   |
| Smoker                                           | 1.64 (0.26, 3.02)    | 0.020   |
| Previous MI                                      | 5.31 (2.09, 8.52)    | 0.001   |
| Infarct size at baseline, %                      | 0.66 (0.61, 0.71)    | <0.001  |
IMR = index of microvascular resistance, TIMI = thrombolysis in myocardial infarction. Other variables included are Previous PCI (P=0.108), Percentage residual stenosis (P=0.258), Diabetes mellitus (P=0.399), Previous Angina (P=0.503), Hypertension (P=0.511), Sex (P=0.516), ST segment resolution- none (P=0.543), Systolic blood pressure per 10mmHg (P=0.565), Heart rate, bmp (P=0.615), Age, years (P=0.755), BMI, kg/m² (P=0.773), Symptoms to reperfusion time per 10 min (P=0.792), Hypercholesterolemia (P=0.799), ST segment resolution- partial (P=0.913).
Supplemental References:

1. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. *Journal of cardiovascular magnetic resonance* : official journal of the Society for Cardiovascular Magnetic Resonance 2013; 15:91.

2. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation* 2002; 105:539-542.

3. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van’t Hof A, Widimsy P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *European heart journal* 2012; 33:2569-2619.

4. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Lauffer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *European heart journal* 2014; 35:2541-2619.

5. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. *JACC Cardiovascular imaging* 2011; 4:150-156.

6. Fearon WF, Shah M, Ng M, Brinton T, Wilson A, Tremmel JA, Schnittger I, Lee DP, Vagelos RH, Fitzgerald PJ, Yock PG, Yeung AC. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. *Journal of the American College of Cardiology* 2008; 51:560-565.

7. McGeoch R, Watkins S, Berry C, Steedman T, Davie A, Byrne J, Hillis S, Lindsay M, Robb S, Dargie H, Oldroyd K. The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial infarction. *JACC Cardiovascular interventions* 2010; 3:715-722.

8. Payne AR, Berry C, Doolin O, McEntegart M, Petrie MC, Lindsay MM, Hood S, Carrick D, Tzemos N, Weale P, McComb C, Foster J, Ford I, Oldroyd KG. Microvascular Resistance Predicts Myocardial Salvage and Infarct Characteristics in
9. M Fukunaga, K Fujii, D Kawasaki, H Sawada, K Miki, H Tamatu, T Imanaka, T Iwasaku, T Nakata, M Shibuya, H Akahori, M Masutani, K Kobayashi, M Ohyanagi, T Masuyama. Thermodilution-Derived Coronary Blood Flow Pattern Immediately After Coronary Intervention as a Predictor of Microcirculatory Damage and Midterm Clinical Outcomes in Patients with ST-Segment-Elevation Myocardial Infarction. Circulation: Cardiovascular Intervention 2014;7:149-155.

10. TIMI-Study-Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. The New England journal of medicine 1985; 312:932-936.

11. Gibson CM, Karha J, Giugliano RP, Roe MT, Murphy SA, Harrington RA, Green CL, Schweiger MJ, Miklin JS, Baran KW, Palmeri S, Braunwald E, Krucoff MW. Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. American heart journal 2004; 147:847-852.

12. Giri S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV, Simonetti OP. T2 quantification for improved detection of myocardial edema. Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance 2009; 11:56.

13. Verhaert D, Thavendiranathan P, Giri S, Mihai G, Rajagopalan S, Simonetti OP, Raman SV. Direct T2 quantification of myocardial edema in acute ischemic injury. JACC Cardiovascular imaging 2011; 4:269-278.

14. Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magnetic resonance in medicine: official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2002; 47:372-383.

15. Wassmuth R, Prothmann M, Utz W, Dieringer M, von Knobelsdorff-Brenkenhoff F, Greiser A, Schulz-Menger J. Variability and homogeneity of cardiovascular magnetic resonance myocardial T2-mapping in volunteers compared to patients with edema. Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance 2013; 15:27.

16. Ghugre NR, Ramanan V, Pop M, Yang Y, Barry J, Qiang B, Connelly KA, Dick AJ, Wright GA. Quantitative tracking of edema, hemorrhage, and microvascular obstruction in subacute myocardial infarction in a porcine model by MRI. Magnetic resonance in medicine: official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2011; 66:1129-1141.

17. Kandler D, Lucke C, Grothoff M, Andres C, Lehmkuhl L, Nitzsche S, Riese F, Mende M, de Waha S, Desch S, Lurz P, Eitel I, Gutberlet M. The relation between hypointense core, microvascular obstruction and intramyocardial haemorrhage in
acute reperfused myocardial infarction assessed by cardiac magnetic resonance imaging. European Radiology 2014;24:3277-88.

18. O'Regan DP, Ariff B, Neuwirth C, Tan Y, Durighel G, Cook SA. Assessment of severe reperfusion injury with T2* cardiac MRI in patients with acute myocardial infarction. Heart 2010; 96:1885-1891.

19. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. European heart journal 2001; 22:2171-2179.

20. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, Thiele H. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Journal of the American College of Cardiology 2010; 55:2470-2479.

21. Berry C, Kellman P, Mancini C, Chen MY, Bandettini WP, Lowrey T, Hsu LY, Aletras AH, Arai AE. Magnetic resonance imaging delineates the ischemic area at risk and myocardial salvage in patients with acute myocardial infarction. Circulation Cardiovascular imaging 2010; 3:527-535.

22. Payne AR, Casey M, McClure J, McGeoch R, Murphy A, Woodward R, Saul A, Bi X, Zuehlsdorff S, Oldroyd KG, Tzemos N, Berry C. Bright-blood T2-weighted MRI has higher diagnostic accuracy than dark-blood short tau inversion recovery MRI for detection of acute myocardial infarction and for assessment of the ischemic area at risk and myocardial salvage. Circulation Cardiovascular imaging 2011; 4:210-219.

23. Francone M, Bucciarelli-Ducci C, Carbone I, Canali E, Scardala R, Calabrese FA, Sardella G, Mancone M, Catalano C, Fedele F, Passariello R, Bogaert J, Agati L. Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magnetic resonance. Journal of the American College of Cardiology 2009; 54:2145-2153.

24. van Kranenburg M, Magro M, Thiele H, de Waha S, Eitel I, Cochet A, Cottin Y, Atar D, Buser P, Wu E, Lee D, Bodi V, Klug G, Metzler B, Delewi R, Bernhardt P, Rottbauer W, Boersma E, Zijlstra F, van Geuns RJ. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovascular imaging 2014; 7:930-939.